Promoter sequence of shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2

mBio

Volumn 4, Issue 5, 2013, Pages

  Bentancor, Leticia V ^a,b   Mejías, Maria P ^a   Pinto, Alípio ^c   Bilen, Marcos F ^b   Meiss, Roberto ^a   Rodriguez Galán, Maria C ^d   Baez, Natalia ^d   Pedrotti, Luciano P ^d   Goldstein, Jorge ^c   Ghiringhelli, Pablo D ^b   Palermo, Marina S ^a  

^a ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^b UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; VEROTOXIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BRAIN TISSUE; CONTROLLED STUDY; CYTOTOXICITY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VIVO STUDY; KIDNEY PARENCHYMA; MALE; MAMMAL CELL; MOUSE; NEUTROPHIL; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROKARYOTIC CELL; PROMOTER REGION; PROTEIN SYNTHESIS; STX2 GENE; TOXIN SYNTHESIS; UREA BLOOD LEVEL;

ANIMALS; BRAIN; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; PROMOTER REGIONS, GENETIC; SHIGA TOXIN 2;

EID: 84887150592     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00501-13     Document Type: Article

References (51)

1. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga toxin-producing Escherichia coli and hemolytic uremic syndrome. Lancet 365:1073-1086.
2. Karmali MA. 1989. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 2:15-38.
3. Karmali MA, Steele BT, Petric M, Lim C. 1983. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet i:619-620.
4. Palermo MS, Exeni RA, Fernández GC. 2009. Hemolytic uremic syndrome: pathogenesis and update of interventions. Expert Rev. Anti Infect. Ther. 7:697-707.
5. Kaper JB, Nataro JP, Mobley HL. 2004. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2:123-140.
6. Herold S, Karch H, Schmidt H. 2004. Shiga toxin-converting bacteriophages. Genomes in motion. Int. J. Med. Microbiol. 294:115-121.
7. Wagner PL, Neely MN, Zhang X, Acheson DW, Waldor MK, Friedman DI. 2001. Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain. J. Bacteriol. 183:2081-2085.
8. Shaikh N, Tarr PI. 2003. Escherichia coli O157:H7 Shiga toxin-encoding bacteriophages: integrations, excisions, truncations, and evolutionary implications. J. Bacteriol. 185:3596-3605.
9. Laing CR, Zhang Y, Gilmour MW, Allen V, Johnson R, Thomas JE, Cannon VPJ. 2013. A comparison of Shiga. toxin 2 bacteriophage from classical enterohemorrhagic Escherichia coli serotypes and the German E. coli O104:H4 outbreak strain. Plos One 7:e37362. doi: 10.1371/ journal.pone.0037362.
10. Kimmitt PT, Harwood CR, Barer MR. 2000. Toxin gene expression by Shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response. Emerg. Infect. Dis. 6:458-465.
11. Schmidt H. 2001. Shiga-toxin-converting bacteriophages. Res. Microbiol. 152:687-695.
12. Cornick NA, Helgerson AF, Mai V, Ritchie JM, Acheson DW. 2006. In vivo transduction of an Stx-encoding phage in ruminants. Appl. Environ. Microbiol. 72:5086-5088.
13. Imamovic L, Jofre J, Schmidt H, Serra-Moreno R, Muniesa M. 2009. Phage-mediated Shiga toxin 2 gene transfer in food and water. Appl. Environ. Microbiol. 75:1764-1768.
14. Strauch E, Lurz R, Beutin L. 2001. Characterization of a Shiga toxinencoding temperate bacteriophage of Shigella sonnei. Infect. Immun. 69: 7588-7595.
15. de Sablet T, Chassard C, Bernalier-Donadille A, Vareille M, Gobert AP, Martin C. 2009. Human microbiota-secreted factors inhibit Shiga toxin synthesis by enterohemorrhagic Escherichia coli O157 H7. Infect. Immun. 77:783-790.
16. Thorpe CM, Smith WE, Hurley BP, Acheson DW. 2001. Shiga toxins induce, superinduce, and stabilize a variety of C-X-C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infect. Immun. 69:6140-6147.
17. Bentancor LV, Bilen MF, Mejías MP, Fernández-Brando RJ, Panek CA, Ramos MV, Fernández GC, Isturiz M, Ghiringhelli PD, Palermo MS. 2013. Functional capacity of Shiga-toxin promoter sequences in eukaryotic cells. PLoS One 8:e57128. doi: 10.1371/journal.pone.0057128.
18. Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258-1266.
19. Liu D, Knapp JE. 2001. Hydrodynamics-based gene delivery. Curr. Opin. Mol. Ther. 3:192-197.
20. Xiao J, Jethanandani P, Ziober BL, Kramer RH. 2003. Regulation of alpha7 integrin expression during muscle differentiation. J. Biol. Chem. 278:49780-49788.
21. Rodriguez-Galán MC, Bream JH, Farr A, Young HA. 2005. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression. J. Immunol. 174:2796-2804.
22. Chen TH, Yeh CT, Ho YP, Hsu CM, Huang CC, Shiau SS, Liang CK, Chang ML. 2009. Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabetic mice. Endocr. J. 56:783-790.
23. Bentancor LV, Bilen M, Brando RJ, Ramos MV, Ferreira LC, Ghiringhelli PD, Palermo MS. 2009. A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin. Vaccine Immunol. 16:712-718.
24. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. 1985. The association between idiopathic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:775-782.
25. Fernandez GC, Lopez MF, Gomez SA, Ramos MV, Bentancor LV, Fernandez-Brando RJ, Landoni VI, Dran GI, Meiss R, Isturiz MA, Palermo MS. 2006. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Clin. Exp. Immunol. 146:76-84.
26. MV, Fernández GC, Meiss R, Rivas M, Palermo MS. 2008. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Clin. Exp. Immunol. 153:297-306.
27. Tironi-Farinati C, Loidl CF, Boccoli J, Parma Y, Fernandez-Miyakawa ME, Goldstein J. 2010. Intracerebroventricular Shiga toxin 2 increases the expression of its receptor globotriaosylceramide and causes dendritic abnormalities. J. Neuroimmunol. 222:48-61.
28. Eng LF, Ghirnikar RS. 1994. GFAP and astrogliosis. Brain Pathol. 4:229-237.
29. Landoni VI, Schierloh P, de Campos Nebel M, Fernández GC, Calatayud C, Lapponi MJ, Isturiz MA. 2012. Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factoralpha that alters brain-like endothelium integrity. PLoS Pathog. 8:e1002632. doi: 10.1371/journal.ppat.1002632.
30. Boccoli J, Loidl CF, Lopez-Costa JJ, Creydt VP, Ibarra C, Goldstein J. 2008. Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains. Brain Res. 1230:320-333.
31. Paetau A, Elovaara I, Paasivuo R, Virtanen I, Palo J, Haltia M. 1985. Glial filaments are a major brain fraction in infantile neuronal ceroidlipofuscinosis. Acta Neuropathol. 65:190-194.
32. Fujii J, Kita T, Yoshida S, Takeda T, Kobayashi H, Tanaka N, Ohsato K, Mizuguchi Y. 1994. Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H-7 in mitomycin-treated mice. Infect. Immun. 62:3447-3453.
33. Goldstein J, Loidl CF, Creydt VP, Boccoli J, Ibarra C. 2007. Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study. Brain Res. 1161: 106-115.
34. Robertson CL, Puskar A, Hoffman GE, Murphy AZ, Saraswati M, Fiskum G. 2006. Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp. Neurol. 197:235-243.
35. Mejias MP, Ghersi G, Craig PO, Panek CA, Bentancor LV, Baschkier A, Goldbaum FA, Zylberman V, Palermo MS. 2013. Immunization with a chimera between the B subunit of Shiga toxin type 2 and Brucella lumazine synthase confers total protection against Shiga toxins. J. Immunol. 191: 2403-2411.
36. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, Acheson DW. 2000. Quinolone antibiotics induce Shiga toxin encoding bacteriophages, toxin production, and death in mice. J. Infect. Dis. 181:664-670.
37. Imamovic L, Muniesa M. 2012. Characterizing RecA-independent induction of shigatoxin 2-encoding phages by EDTA treatment. PLoS One 7:e32393. doi: 10.1371/journal.pone.0032393.
38. Guo ZS, Wang LH, Eisensmith RC, Woo SL. 1996. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirusmediated gene transfer. Gene Ther. 3:802-810.
39. Karmali MA. 2004. Infection by Shiga toxin-producing Escherichia coli: an overview. Mol. Biotechnol. 26:117-122.
40. Cimolai N, Carter JE. 1998. Bacterial genotype and neurological complications of Escherichia coli O157:H7-associated haemolytic uraemic syndrome. Acta Paediatr. 87:593-594.
41. Eriksson KJ, Boyd SG, Tasker RC. 2001. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch. Dis. Child. 84: 434-435.
42. Sheth KJ, Swick HM, Haworth N. 1986. Neurologic involvement in hemolytic uremic syndrome. Ann. Neurol. 19:90-99.
43. Hahn JS, Havens PL, Higgins JJ, O'Rourke PP, Estroff JA, Strand R. 1989. Neurological complications of hemolytic uremic syndrome. J. Child Neurol. 4:108-113.
44. Karch H, Denamur E, Dobrindt U, Finlay BB, Hengge R, Johannes L, Ron EZ, Tonjum T, Sansonetti PJ, Vincete M. 2012. The enemy within us: lessons from the 2011 European Escherichia coli O104:H4 outbreak. EMBO Mol. Med. 4:841-848.
45. Petruzziello-Pellegrini TN, Marsden PA. 2012. Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr. Opin. Nephrol. Hypertens. 21:433-440.
46. Milford D, Taylor CM, Rafaat F, Halloran E, Dawes J. 1989. Neutrophil elastases and haemolytic uraemic syndrome. Lancet ii:1153.
47. Fitzpatrick MM, Shah V, Filler G, Dillon MJ, Barratt TM. 1992. Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma. Pediatr. Nephrol. 6:50-53.
48. Unal-Cevik I, Kilinç M, Gürsoy-Ozdemir Y, Gurer G, Dalkara T. 2004. Loss of NeuN immunoreactivity after cerebral ischemia does not indicate neuronal cell loss: a cautionary note. Brain Res. 1015:169-174.
49. Capozzo AV, Pistone Creydt V, Dran G, Fernández G, Gómez S, Bentancor LV, Rubel C, Ibarra C, Isturiz M, Palermo MS. 2003. Development of DNA vaccines against hemolytic-uremic syndrome in a murine model. Infect. Immun. 71:3971-3978.
50. Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
51. Parma YR, Chacana PA, Lucchesi PM, Rogé A, Granobles Velandia CV, Kruger A, Parma AE, Fernandez-Miyakawa ME. 2012. Detection of Shiga toxin-producing Escherichia coli by sandwich enzyme-linked immunosorbent assay using chicken egg yolk IgY antibodies. Front Cell. Infect Microbiol. 2:84. doi: 10.3389/fcimb.2012.00084.